Giovana Seno Di Marco

Dr. Giovana Seno Di Marco

University Hospital Münster, Münster, North Rhine-Westphalia, Germany
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2011 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CFChristian Faul
Christian Faul
AAAnsel P. Amaral
Ansel P. Amaral
BOBehzad Oskouei
Behzad Oskouei
MHMing-Chang Hu
Ming-Chang Hu
ASAlexis Sloan
Alexis Sloan
MWMyles Wolf
Myles Wolf
Chronic kidney disease (CKD) is a public health epidemic that increases risk of death due to cardiovascular disease. Left ventricular hypertrophy (LVH) is an important mechanism of cardiovascular disease in individuals with CKD. Elevated levels of FGF23 have been linked to greater risks of LVH and mortality in patients with CKD, but whether these risks represent causal effects of FGF23 is unknown. Here, we report that elevated FGF23 levels are independently associated with LVH in a large, racially diverse CKD cohort. FGF23 caused pathological hypertrophy of isolated rat cardiomyocytes via FGF receptor–dependent activation of the calcineurin-NFAT signaling pathway, but this effect was independent of klotho, the coreceptor for FGF23 in the kidney and parathyroid glands. Intramyocardial or intravenous injection of FGF23 in wild-type mice resulted in LVH, and klotho-deficient mice demonstrated elevated FGF23 levels and LVH. In an established animal model of CKD, treatment with an FGF–receptor blocker attenuated LVH, although no change in blood pressure was observed. These results unveil a klotho-independent, causal role for FGF23 in the pathogenesis of LVH and suggest that chronically elevated FGF23 levels contribute directly to high rates of LVH and mortality in individuals with CKD.

1 December 2015 in Cell Metabolism
Verified
Journal Article
Closed access
AGAlexander Grabner
Alexander Grabner
AAAnsel P. Amaral
Ansel P. Amaral
KSKarla Schramm
Karla Schramm
SSSaurav Singh
Saurav Singh
ASAlexis Sloan
Alexis Sloan
CFChristian Faul
Christian Faul

1 November 2016 in Kidney International
Verified
Journal Article
Closed access
SSSaurav Singh
Saurav Singh
AGAlexander Grabner
Alexander Grabner
CYChristopher Yanucil
Christopher Yanucil
KSKarla Schramm
Karla Schramm
BCBrian Czaya
Brian Czaya
CFChristian Faul
Christian Faul

1 June 2014 in Atherosclerosis
Verified
Journal Article
Closed access
JPJan-Sören Padberg
Jan-Sören Padberg
AWAnne Wiesinger
Anne Wiesinger
GMGiovana Seno Di Marco
Giovana Seno Di Marco
SRStefan Reuter
Stefan Reuter
AGAlexander Grabner
Alexander Grabner
PKPhilipp Kümpers
Philipp Kümpers

1 June 2008 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
PDF file
GMGiovana Seno Di Marco
Giovana Seno Di Marco
MHM. Hausberg
M. Hausberg
UHU. Hillebrand
U. Hillebrand
PRP. Rustemeyer
P. Rustemeyer
WWW. Wittkowski
W. Wittkowski
HPH. Pavenstädt
H. Pavenstädt
Chronic kidney disease with hyperphosphatemia is associated with accelerated atherosclerosis and endothelial dysfunction. However, the contribution of high serum phosphate levels to endothelial injury is incompletely understood. The aim of this work was to evaluate the responses of endothelial cells to elevated levels of extracellular phosphate in vitro. High phosphate in concentrations similar to those observed in uremia-associated hyperphosphatemia (>2.5 mM) induced apoptosis in two endothelial cell lines (EAhy926 cells and GM-7373 cells). This effect was enhanced when cells were incubated for 24 h in the presence of 2.8 mM calcium instead of 1.8 mM. By treating cells with 0.5 or 1.0 mM phosphonoformic acid, an inhibitor of the phosphate transporter, death was completely prevented. The process of phosphate-induced apoptosis was further characterized by increased oxidative stress, as detected by increased ROS generation and disruption of the mitochondrial membrane potential at ∼2 h after treatment, followed by caspase activation. These findings show that hyperphosphatemia causes endothelial cell apoptosis, a process that impairs endothelial integrity. Endothelial cell injury induced by high phosphate concentrations may be an initial event leading to vascular complications in patients with chronic kidney disease.

1 October 2009 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
GMGiovana Seno Di Marco
Giovana Seno Di Marco
SRStefan Reuter
Stefan Reuter
UHUta Hillebrand
Uta Hillebrand
SASusanne Amler
Susanne Amler
MKMaximilian König
Maximilian König
MBMarcus Brand
Marcus Brand
Endothelial dysfunction contributes to the increased cardiovascular risk that accompanies CKD. We hypothesized that the soluble VEGF receptor 1 (sFlt-1), a VEGF antagonist, plays a role in endothelial dysfunction and decreased angiogenesis in CKD. We enrolled 130 patients with CKD stages 3 to 5 and 56 age- and gender-matched control patients. Plasma sFlt-1 levels were higher in patients with CKD and, after multivariate regression analyses, exclusively associated with renal function and levels of vWF, a marker of endothelial dysfunction. Compared with serum from control patients, both recombinant sFlt-1 and serum from patients with CKD had antiangiogenic activity in the chick chorioallantoic membrane (CAM) assay, induced endothelial cell apoptosis in vitro, and decreased nitric oxide generation in two different endothelial cell lines. Pretreating the sera with an antibody against sFlt-1 abrogated all of these effects. Furthermore, we observed increased sFlt1 levels in 5/6-nephrectomized rats compared with sham-operated animals. Finally, using real-time PCR and ELISA, we identified monocytes as a possible source of increased sFlt-1 in patients with CKD. Our findings show that excess sFlt-1 associates with endothelial dysfunction in CKD and suggest that increased sFlt-1 may predict cardiovascular risk in CKD.